FDA Oncology Announcements

Announcements Trials

Anti-dabigatran antibody fragment × Clear all

Conditions

Drug Classes

Anti-PD-1 98 Anti-PD-L1 28 Anti-CD20 24 Platinum agent 21 Immunomodulatory drugs (IMiDs) 20 Taxane 20 VEGFR inhibitor 20 BTK inhibitor 18 Bcr-Abl inhibitor 18 Anti-CD38 17 PARP inhibitor 17 Anti-HER2 16 Anti-VEGFR 16 BRAF inhibitor 16 EGFR inhibitor 16 Proteasome inhibitor 16 ALK inhibitor 14 Anti-CD19 CAR T-cell 14 Anti-CTLA-4 13 MEK inhibitor 13 Anti-EGFR 12 MTOR inhibitor 11 Anti-HER2 ADC 10 Second-generation nonsteroidal antiandrogen 10 Antifolate 9 CDK inhibitor 9 Multikinase inhibitor 9 Nitrogen mustard 9 Pyrimidine analog 9 RET inhibitor 9 ERBB2 inhibitor 8 IDH inhibitor 8 Anti-CD30 ADC 7 Estrogen receptor inhibitor 7 Fluoropyrimidine 7 Megakaryocyte growth factor 7 Alkylating agent 6 Anthracycline 6 Bcl-2 inhibitor 6 DNA methyltransferase inhibitor 6 FGFR inhibitor 6 Anti-CD20-CD3 bispecific 5 Anti-EGFR-HGFR bispecific 5 Anti-nectin-4 ADC 5 Asparagine-specific enzyme 5 JAK inhibitor 5 Radioactive agent 5 Anti-BCMA-CD3 bispecific 4 Anti-CD19-CD3 bispecific 4 Anti-TACSTD2 ADC 4 HDAC inhibitor 4 KRAS inhibitor 4 MET inhibitor 4 Multi-ingredient 4 PI3K delta inhibitor 4 Anti-RANKL 3 CYP17 inhibitor 3 FLT3 inhibitor 3 HIF-2a inhibitor 3 KMT2A inhibitor 3 Non-taxane microtubule dynamics inhibitor 3 PDGFR inhibitor 3 PI3K alpha inhibitor 3 ROS1 inhibitor 3 TRK inhibitor 3 Topoisomerase I inhibitor 3 XPO1 inhibitor 3 AKT1 inhibitor 2 Anti-BCMA CAR T-cell 2 Anti-BCMA ADC 2 Anti-CD19 2 Anti-CD22 ADC 2 Anti-CD33 ADC 2 Anti-CD79B ADC 2 Anti-DLL3-CD3 bispecific 2 Anti-FOLR1 ADC 2 Anti-GD2 2 Anti-TF ADC 2 Anti-TROP2 ADC 2 Aromatase inhibitor third generation 2 EZH inhibitor 2 Erythrocyte growth factor 2 Factor IXa/Xa bridging 2 GnRH antagonist 2 Granulocyte colony-stimulating factor 2 IL-3 fused immunotoxin 2 Low molecular weight heparin 2 Purine analog 2 SMO inhibitor 2 STAMP inhibitor 2 TGF-beta inhibitor 2 Topoisomerase II inhibitor 2 Adenovirus vector 1 Anti-C5 1 Anti-CCR4 1 Anti-CD19 ADC 1 Anti-CD22 immunotoxin 1 Anti-CLDN18.2 1 Anti-CSF1R 1 Anti-GPRC5D-CD3 bispecific 1 Anti-HER2 bispecific 1 Anti-HER2-HER3 bispecific 1 Anti-IFNg 1 Anti-IL-2R immunotoxin 1 Anti-IL-6 1 Anti-MAGE-A4 SPEAR T-cell 1 Anti-P-selectin 1 Anti-PDGFR 1 Anti-SLAMF7 1 Anti-c-Met ADC 1 Anti-dabigatran antibody fragment 1 Anti-vWF 1 Antimetabolite 1 Bispecific gp100 peptide-HLA-directed CD3 T-cell engager 1 CSF1R inhibitor 1 CXCR4 inhibitor 1 Cellular therapy 1 Chemotherapy protective agent 1 EDTA derivative 1 Factor Xa inhibitor 1 Gamma secretase inhibitor 1 Glucocorticoid receptor antagonist 1 Hedgehog pathway inhibitor 1 Hemoglobin S polymerization inhibitor 1 IL-15 receptor alpha fusion protein 1 Interferon 1 Iron chelating agent 1 Mononuclear cell vaccine 1 Oncolytic viral therapy 1 Ornithine decarboxylase inhibitor 1 Peptidase-enhanced nitrogen mustard 1 Profibrinolytic 1 ROCK2 inhibitor 1 Replacement therapy 1 SYK inhibitor 1 Selective estrogen receptor modulator 1 Somatostatin analog 1 Telomerase inhibitor 1 Triazene 1 Vinca alkaloid 1

1 Announcement

Idarucizumab

Drug: Praxbind (idarucizumab) · Anti-dabigatran antibody fragment

Data powered by HemOnc (CC BY 4.0) Colophon ⚡